Disclosures

Personal Commercial (0)

No disclosures on record

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (5)

<table>
<thead>
<tr>
<th>Trial Name</th>
<th>Trial Sponsor</th>
<th>Trial Funding Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>CSL Bering</td>
<td>A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of XXX in Subjects with Acute Coronary Syndrome</td>
<td>CSL Bering</td>
</tr>
<tr>
<td>Target BPI</td>
<td>A Phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population: The dal-GenE trial</td>
<td>Target BPI</td>
</tr>
<tr>
<td>Open-Label, Sequential-Dose Escalation/De-escalation Trial Testing XXXXX in Patients Undergoing PCI Due to Acute Coronary Syndrome with NSTEMI</td>
<td>Shaanxi Micot Technology Co. Ltd</td>
<td>Open-Label, Sequential-Dose Escalation/De-escalation Trial Testing XXXXX in Patients Undergoing PCI Due to Acute Coronary Syndrome with NSTEMI</td>
</tr>
<tr>
<td>The OPTIMIZE Trial to Assess the Procedural and Clinical Value of the Svelte IDS and RX Sirolimus Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions in a Randomized Study</td>
<td>Svelte Medical Systems</td>
<td>The OPTIMIZE Trial to Assess the Procedural and Clinical Value of the Svelte IDS and RX Sirolimus Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions in a Randomized Study</td>
</tr>
</tbody>
</table>

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

Agreement

Certified Education Attestation | Signed on 7/23/2023
URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 7/23/2023
URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 7/23/2023
URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 7/23/2023

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College’s integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.